MIF-1 is an endogenous tripeptide neuromodulator that crosses the BBB and modulates dopamine receptors and neuropeptide release. It shows antidepressant, nootropic, and anti-Parkinsonian effects with rapid onset and minimal side effects in studies.
MIF-1
Also known as: Melanocyte-Inhibiting Factor; Pro-Leu-Gly-NH2; Melanostatin
Overview
Benefits
- Antidepressant effects
- Cognitive enhancement
- Motor control support
- Addiction support
Consider This Peptide If You Want To
- Support mood regulation and mental well-being
- Enhance cognitive function and neuroprotection
Dosage & Administration
Dosage Guidelines
Recommended Dosage
• Amount:5 mg
• Frequency:weekdays
• Duration:1 week
• Rest Period:1 week
• Time of Day:morning
• Ingestion:subcutaneous
Administration Routes:SubcutaneousOral
Oral Administration:
• Standard Dosage: 60-75 mg daily
• Timing:
• Duration:
Research Findings on Dosage:
• Subcutaneous Injection:
◦ Commonly Reported Dosage: 10 mg once daily
◦ Duration: 5 days. Repeat cycles after a 1--2-week interval as needed.
• Oral Administration:
◦ Commonly Reported Dosage: 60--75 mg daily, divided into smaller doses or taken once per day.
Mechanism of Action
Mechanism of Action
How this peptide works in the body
Acts as a positive allosteric modulator for D2 and D4 dopamine receptors, increasing their responsiveness to dopamine. This interaction stabilizes neurotransmission, promoting mood enhancement and cognitive function by increasing cAMP signaling and reducing excitotoxicity.
Inhibits opioid receptor activation by reducing receptor binding affinity for endogenous opioids, contributing to its anti-addictive and mood-regulating properties. This action involves interference with the G-protein coupled receptor pathways.
Inhibition of Alpha-MSH Release:
Neurotransmitter Regulation:
Enhances norepinephrine and dopamine levels in specific brain regions such as the striatum and cortex, influencing mood and motivation. This regulation is achieved through altered reuptake transporter dynamics and enzyme inhibition, including monoamine oxidase.
Modulates the hypothalamic-pituitary axis by decreasing melanocyte-stimulating hormone secretion, thus impacting neuropeptide balance and influencing stress and mood responses. The reduction occurs via direct inhibition of prohormone convertase enzymes.
Neurotransmitter Regulation:
Enhances norepinephrine and dopamine levels in specific brain regions such as the striatum and cortex, influencing mood and motivation. This regulation is achieved through altered reuptake transporter dynamics and enzyme inhibition, including monoamine oxidase.
Consider Stacking With
- Cerebrolysin (nootropic peptides)
- Anti-inflammatory agents
- Dopamine agonists
Side Effects & Cautions
Common Side Effects
- Generally well-tolerated; rare mild GI discomfort or headache
Cautions
- Avoid concurrent use with opioid medications (may negate effects)
Rare Side Effects
- Unusual sensitivity reactions in atypical peptide metabolism
Research & References
Research Highlights
Antidepressant Activity: Clinical trials demonstrate rapid and sustained relief from depressive symptoms, outperforming standard treatments like SSRIs in initial response times.
Neuroprotection: Research shows reduced neuroinflammation and protection against ischemic brain injury.
Kastin, A. J., et al., "Clinical Implications of MIF-1 in Depression Treatment," Journal of Neuroendocrinology, 1980
Smith, R. et al., "Mechanistic Insights into MIF-1 Neuroprotection," Peptide Science Advances, 2023
Nycomed Data, "Therapeutic Peptides: MIF-1 and Beyond," 2022
Sundberg, P., "MIF-1 in Opioid Receptor Modulation," International Journal of Neuropharmacology, 2023
Smith, R. et al., "Mechanistic Insights into MIF-1 Neuroprotection," Peptide Science Advances, 2023
Nycomed Data, "Therapeutic Peptides: MIF-1 and Beyond," 2022
Sundberg, P., "MIF-1 in Opioid Receptor Modulation," International Journal of Neuropharmacology, 2023